Compare Humana Inc (HUM) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Raytheon Technologies Corp — how do they compare? Humana Inc trades at $431.03 (market cap $46.49B), while Raytheon Technologies Corp trades at $185.97 (market cap $248.42B). The key difference: Raytheon Technologies Corp is far larger — about 5.3× Humana Inc's market cap, and Raytheon Technologies Corp pays the higher dividend (1.58%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Raytheon Technologies Corp for 77 Days on average.
| HUM | RTX | |
|---|---|---|
Market Cap | $46.49B | $248.42B |
Volume | 2,567,704 | 4,380,368 |
Sector | Health | Industrials |
52-Week High | $409.85 | $225.49 |
52-Week Low | $163.67 | $157.00 |
Typical Hold Time | 51 Days | 77 Days |
Enterprise Value | $53.84B | $278.97B |
Dividend Yield | 0.91% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
RTX trades at $184.32, up 2.25% with strong earnings momentum as Q1 and Q2 2026 results beat expectations. The stock shows bearish technical signals but benefits from a $289 billion backlog and rising defense spending. Revenue grew to $88.6 billion in 2025 with net income of $6.73 billion, while analyst consensus remains bullish with a $236.27 price target.
Outlook is positive given defense budget tailwinds and operational execution, though technical weakness and debt levels pose risks. The company's dividend and backlog provide stability, but investors should monitor geopolitical impacts and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
